Objectives: Premature adrenarche has been reported to be frequent in Silver-Russell syndrome (SRS), but systematic studies are lacking. Here, we studied the prevalence of early adrenarche in SRS, potential predictors, and consequences based on cases with long-term follow-up.
S ilver-Russell syndrome (SRS) is characterized by severe intrauterine growth restriction, failure to thrive during infancy, low body mass index, short stature, relative macrocephaly, a protruding forehead, and body asymmetry (1, 2) . At least four of these criteria are needed for diagnosis according to the most recent international guidelines (3) . The most frequent epigenetic cause of this syndrome is hypomethylation of the paternal H19/IGF2: IG-DMR locus on 11p15 (11p15 LOM), which is involved in the regulation of IGF2 expression (4) . A less frequent cause is maternal uniparental disomy of chromosome 7 [upd (7) mat] (5). Monogenic causes, which are very rare, include mutations of CDKN1C and IGF2, both located on 11p15 (6, 7) .
Most children with SRS remain short and underweight, and adult heights are frequently .3 standard deviations below the mean (8) . Treatment with recombinant human growth hormone (rhGH) is used to promote growth, with similar success as in nonsyndromic children born small for gestational age (SGA) (9) (10) (11) . However, premature maturation with early adrenarche and early gonadarche seems to be frequent in SRS and may compromise initial catch-up growth due to rhGH treatment, resulting in a lowered predicted adult height (3) . Adrenarche is defined by a substantial rise of serum dehydroepiandrosterone (DHEAS) to .500 ng/mL (12) and is followed by pubarche after a time interval ranging from a few months to .1 year. Premature adrenarche is a clinical entity classically defined by the clinical sign of pubarche at an age ,8 years in girls and 9 years in boys (12) . In children without SRS, premature adrenarche has been linked to low birthweight but also to early growth acceleration in infancy and to overweight, depending on the study design and selection of patients (13) (14) (15) . Studies of adrenarche in SRS are lacking. Expert opinion is that premature adrenarche is frequent in these children (3) . Here, we report a longitudinal study of adrenarche in SRS based on the clinical and biochemical data of a cohort of 62 patients with SRS seen during the last 20 years in our center.
The aim of the study was to analyze whether early adrenarche is associated with the severity of the syndrome or with early initiation of rhGH treatment and to determine whether early adrenarche compromises the outcome of rhGH treatment.
Patients
On the basis of the patient records and clinical data files of the Pediatric Endocrinology Section in Tübingen, we identified 104 patients with a diagnosis of SRS who were seen during the past 20 years. Of these 104 patients with SRS, 14 were lost to follow-up, 19 were still preadrenarcheal, 3 presented first after adrenarche, and 6 had insufficient documentation. This analysis uses the data from the remaining 62 patients with documented age at adrenarche. Adult height has been reached by 43 patients. The mean follow-up time was 12.8 years (quartiles: 8.2, 15.4 years). During this time period, routine visits took place every 6 months and included physical examination and blood analysis with measurement of DHEAS.
We used the Netchine-Harbison clinical scoring system (16) to exclude patients who were unlikely to have SRS. Only patients fulfilling at least four of the six scoring criteria (severe intrauterine growth restriction, failure to thrive during infancy, short stature during childhood, relative macrocephaly, prominent forehead, and skeletal asymmetry) were included in this analysis. Patients who were diagnosed with SRS on the basis of upd(7)mat or 11p15 LOM genotypes but did not fulfill the clinical criteria of the score were also included. Children with relative microcephaly were excluded because this sign makes the diagnosis of SRS unlikely (3). Treatment with rhGH for short stature was prescribed in 60 patients and was initiated before adrenarche (DHEAS . 500 ng/mL) in 56 patients. Gonadotropin-releasing hormone analog (GnRHa; leuprolide 3.75 mg subcutaneously per month) treatment of the suppression of early puberty (not precocious puberty) was administered to 23 patients who were receiving rhGH treatment (12 girls). The aim of this add-on therapy with leuprolide was to improve the growth outcome.
This retrospective study was performed in accordance with the guidelines of the Helsinki Declaration and was approved by the Medical Ethics Committee of the University of Tübingen.
Materials and Methods
All data had been collected and systematically recorded by experienced pediatric endocrinologists at the University Children's Hospital in Tübingen, Germany. Data were extracted from the patients' files and entered in an Excel spreadsheet (Microsoft Corp., Redmond, WA). The following items were collected: birthweight, length at birth, and birth head circumference, as well as gestational age at birth; height, weight, bone age, and pubertal stage from first to last presentation; rhGH dose and supplemental therapy with GnRHa; age at menarche; familial target height; and adult height. In addition, serum concentrations of DHEAS, insulinlike growth factor (IGF)-1, IGF binding protein-3, testosterone, estradiol, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were collected. DHEAS, IGF-1, and IGF binding protein-3 serum concentrations were measured every 6 months. Testosterone, estradiol, LH, and FSH serum concentrations were measured every 6 months in girls age .9 years and boys age .10 years, or at younger age when there was clinical suspicion of gonadarche. The heights of both patients and their parents were measured by using a wall-mounted stadiometer.
Familial target height was defined as the mean of the parents' heights, corrected for sex (66.5 cm). Adult height was defined as the height reached 4 years after gonadarche, at a bone age . 15 years in girls and . 16 years in boys or when the difference between two consecutive height measurements spanning a time interval $6 months was #4 mm. Bone age was estimated by experienced pediatric endocrinologists using the x-ray figures displayed in the Greulich and Pyle atlas.
Age at adrenarche was defined as the age when serum DHEAS first reached a concentration between 500 and 1500 ng/mL (12) . Early adrenarche was defined as the occurrence of this DHEAS rise in girls age ,8 years and in boys age ,9 years.
Premature adrenarche was defined as the clinical finding of pubarche (Tanner stage PH2) in girls age ,8 years and in boys age ,9 years (12). Importantly, there is no definition of premature adrenarche based on DHEAS serum concentration in the literature.
For the analysis of predictors and consequences of adrenarche in SRS, we used the rise in DHEAS as the relevant marker because this biochemical observation is more reliable than the detection of the first pubic hairs (pubarche), which may be missed even by experienced pediatric endocrinologists.
Age at gonadarche in boys was defined as the age at the first presentation when testicular volume was .3 mL, the serum testosterone concentration exceeded 19 ng/dL, or LH was .0.5 IU/L. In girls, this was defined as the age at the first presentation when breast stage B2 on the Tanner scale was reached or the serum LH peak was higher than the serum FSH peak after GnRH challenge (17) . In girls not tested with GnRH, breast stage B2 was accepted as the first sign of gonadarche when accompanied by growth spurt and increase of basal serum LH (.0.4 IU/L) and followed by breast stage B3 at the next clinical visit.
Serum DHEAS concentrations were measured by using an automated chemiluminescence assay system (Immulite; DPC Biermann GmbH, Bad Nauheim, Germany). The interassay coefficient of variation was 8.5%. Serum LH and FSH concentrations were measured by using the ADVIA Centaur XP chemiluminescence assay (Siemens Medical Products, Eschborn, Germany). The interassay coefficients of variation were ,4% and ,8% for LH and FSH, respectively. Serum estradiol concentrations were measured by using the MaiaZen estradiol radioimmunoassay from Radim (Pomezia, Italy). The interassay coefficient of variation was 11.2%. Serum testosterone concentrations were measured by using the Coat-A-Count Total Testosterone radioimmunoassay (Siemens Medical Products). The interassay coefficient of variation was 9.3%. Serum IGF-1 was measured by an in-house radioimmunoassay as described by Blum et al. (18) . The interassay coefficient of variation was 10%. IGF-1 data were transformed into age-specific standard deviation score (SDS) values based on a reference population of healthy German and Danish children of normal height (18) . A Student t test was used to compare the characteristics of the group of children with early adrenarche (girls age ,8 years, boys age ,9 years) with those of the group with normal adrenarche if medians and quartiles suggested a difference.
Statistical analyses
The following factors possibly associated with timing of adrenarche were examined by using the nonparametric Spearman rank-correlation coefficient to evaluate monotonic relationships: the type of epigenetic mutation (11p15 LOM or no genetic defect), the Netchine-Harbison SRS clinical scoring system (score of 3 or 4 vs score of 5 or 6), birthweight SDS, and age at initiation of rhGH treatment. In addition, the relationship between timing of adrenarche and the aforementioned possible predictors was estimated by multiple linear regression analysis.
The relationship between age at adrenarche and age at gonadarche was analyzed. Finally, the associations of adult height SDS, distance to target height (defined by the difference between target height SDS and adult height SDS) and rhGH-induced gain in height SDS (defined by the difference between adult height SDS and height SDS at rhGH treatment initiation) with age at adrenarche were assessed by using Spearman rank-correlation analysis.
Finally, we calculated the residual growth in centimeters after adrenarche and gonadarche and analyzed its dependence on the corresponding age at these maturational steps and on GnRHa treatment.
P values , 0.05 were considered to represent statistically significant differences.
Results
The main characteristics of the study group are shown in Table 1 .
Boys (n = 34) reached adrenarche (DHEAS rise) at a median age of 9.2 years (quartiles: 7.6, 10.9 years), compared with a median age of 8.1 years (quartiles: 6.6, 10.1 years) in girls (n = 28).
Determination of the age at pubarche (PH2) was possible in 51 patients: Boys (n = 27) reached PH2 at a median age of 11.7 years (quartiles: 10.7, 12.8 years), compared with a median age of 9.8 years (quartiles: 8.3, 10.8 years) in girls (n = 24). Premature adrenarche was documented in 8 patients (3 boys) (13%). According to 51 longitudinal observations, pubarche occurred 2.0 years and 1.0 year after adrenarche in boys and girls, respectively (medians).
The age at gonadarche was documented in 51 patients (28 boys): Boys had gonadarche at a median age of 11.9 years (quartiles: 11.3, 12.8 years), compared with a median age of 10.2 years (quartiles: 9.7, 11.1 years) for girls. Precocious puberty occurred in 1 boy (gonadarche at 6.9 years), who had his adrenarche at 2.3 years of age.
Predictors Table 2 shows the main characteristics of the group of patients with early adrenarche (age ,9 years in boys and ,8 years in girls) compared with patients with normal adrenarche. In boys, members of the early adrenarche cohort had lower birthweight, lower age at rhGH initiation, lower bone age at adrenarche, lower age at pubarche, and lower age at gonadarche (P , 0.01) but higher height at gonadarche (P = 0.018). In girls, there was an association with lower bone age at adrenarche, lower age at pubarche, and a longer duration of rhGH treatment (P , 0.01).
Severity of the syndrome
Analysis of patients with low SRS score (score of 3 or 4) (n = 27) vs high SRS score (score of 5 or 6) (n = 35) revealed no significant association with age at adrenarche (P = 0.236 in girls, P = 0.972 in boys). There was a nonsignificant trend toward younger age at adrenarche in girls with 11p15 LOM (median age, 6.7 years; n = 11) compared with clinical SRS (median age, 9.8 years; n = 9) (P = 0.095). In boys, median age at adrenarche was 8.4 years in 11p15 LOM (n = 10) but 9.8 years in those with clinical SRS (n = 11) (P = 0.342).
Birthweight SDS, which is an early measure of the severity of SRS, correlated moderately with age at adrenarche in boys, whereas there was no correlation in girls (boys: rho = 0.380, P = 0.027; girls: rho = 0.105, P = 0.60).
Age at initiation of rhGH treatment
The age at initiation of rhGH treatment was moderately to highly associated with age at adrenarche in both sexes (boys: rho = 0.542, P = 0.001; girls: rho = 0.393, P = 0.039). There was no correlation between the age at initiation of rhGH treatment and the SRS score (P = 0.10). In multivariate regression analysis (28 girls and 32 boys) with age at initiation of rhGH, birthweight SDS, and SRS score as independent parameters and age at adrenarche as the dependent parameter, the age at initiation of rhGH treatment remained the strongest independent predictor of age at adrenarche in both sexes (Table 3 ). In boys, birthweight SDS was an additional independent predictor (Table 3) .
Consequences
Bone age accelerated in both sexes by almost 1 year within the first 2 years after adrenarche (data not shown). Age at adrenarche was highly correlated with age at gonadarche in boys (rho = 0.687; P , 0.001), but there was no association in girls (rho = 0.214; P = 0.326). The single boy with precocious puberty had the earliest adrenarche, at 2.3 years of age. One additional boy had a very young age at adrenarche (2.4 years); he was lost to follow-up before gonadarche. Age at adrenarche was also highly correlated with the age at adult height in boys (rho = 0.62; P = 0.008) but not in girls (rho = 0.19; P = 0.47). The median residual growth after adrenarche was 36.7 cm (quartiles: 31.3, 46.3 cm) in boys (n = 23) and 27.7 cm (quartiles: 21.1, 40.3 cm) in girls (n = 19). This residual growth was strongly correlated with age at adrenarche, with more growth in patients with earlier adrenarche (boys, rho = 20.944, P , 0.001; girls, rho = 20.840, P , 0.001), and seemed not to be influenced by GnRHa treatment (Fig. 1) . The residual growth after adrenarche was adequate for age.
After gonadarche, mean residual growth was 23.4 cm (quartiles: 21.3, 26.5 cm) in boys (n = 22) and 19.5 cm (quartiles: 11.8, 22.4 cm) in girls (n = 19). Importantly, the correlation of residual growth with age at gonadarche was nonsignificant in boys (rho = 20.295, P = 0.182). In girls this correlation was significant (rho = 20.616, P = 0.005) (Fig. 2) . The use of bone age instead of chronologic age did not improve this correlation (data not shown). Girls treated with GnRHa showed more residual growth after gonadarche than those who did not receive GnRHa (Fig. 2) . Figure 3 shows height SDS at initiation of rhGH treatment, at adrenarche, and at gonadarche, as well as at adult height, for 41 patients with complete longitudinal data. Height SDS at adrenarche was comparable with adult height SDS.
Discussion
This is the first systematic longitudinal study of adrenarche in patients with SRS. Here, we collected longitudinal data from a relevant cohort of patients with SRS who differed in age at adrenarche, searched for correlations with clinical severity and age at initiation of rhGH treatment and examined whether early adrenarche compromises the outcome of rhGH treatment.
Median age at adrenarche, defined by reaching a DHEAS serum concentration .500 ng/mL, was 9.2 years in boys and 8.1 years in girls. Therefore, adrenarche was only moderately accelerated by~1 year in both sexes when compared with reference data established by using the same chemiluminescence assay (22, 23) . A comparison with short, nonsyndromic SGA children is difficult because longitudinal studies are lacking. In a crosssectional study, Boonstra et al. (24) observed similar DHEAS serum concentrations in 185 short Dutch children born SGA when compared with normal children.
One of seven patients with SRS had premature adrenarche (13%), which is certainly more frequent than in the general population. However, the prevalence of premature adrenarche in nonsyndromic short children born SGA is not known.
Early rhGH treatment, but not severity of the syndrome, was significantly associated with early adrenarche in both sexes. Although bone age moderately accelerated around adrenarche, this maturation was not followed by a discernible compromise of adult height in those with early adrenarche and did not result in a diminished response to rhGH.
The strongest independent predictor of age at adrenarche was age at rhGH initiation. This relationship between rhGH initiation and age at adrenarche could be confounded by the severity of the syndrome defined by the degree of growth failure and dystrophy as well as by the number and quality of associated syndromic features, Unless otherwise noted, data are expressed as median (quartiles). (n) is given in the case of missing data.
Abbreviations: nd; not done; neg, negative; NH, Netchine-Harbison as median and quartiles. a P , 0.01 (early vs normal).
b P = 0.018 (early vs normal).
as severity of the syndrome could contribute to an earlier presentation to a specialist and an earlier initiation of rhGH. However, based on our cohort with admittedly small numbers in subgroups, we were unable to identify this relationship. Importantly, additional factors, such as the approval of rhGH for SRS in 2003 and the consecutively rising recognition of the syndrome in the medical community, might have influenced the age at first presentation and the age at initiation of rhGH treatment.
There are no comparable studies on SRS. In agreement with our observation, the findings of a randomized controlled trial on short SGA children showed a significant rise in DHEAS during 6 months of treatment in rhGH (60 mg/kg/d) but not in the untreated controls (mean age, 7 years) (25) . A similar rise in DHEAS during rhGH treatment was shown by Boonstra et al. (24) , who retrospectively analyzed serum DHEAS in a large group of SGA children randomly assigned to rhGH treatment (1 or 2 mg/m 2 /d) or no treatment. This study included a wide age range, from 3 to 9 years, and groups were not strictly age-matched. In age group II (mean ages, 6.9 to 7.5 years), the authors observed a trend toward higher DHEAS serum concentrations in the high-dose group; this trend was statistically significant in age group III (mean ages, 8.2 to 9.6 years). These data are consistent with our results and the aforementioned randomized controlled trial (25) . However, when Boonstra et al. (24) adjusted for age in statistical analyses, the trend was no longer statistically significant. The mean rhGH dose in our study is similar to the 60 mg/kg/d dose used in the previous randomized controlled trial (25) and the 2 mg/m 2 /d dose used in the Dutch trial (24) . Is there a biological explanation for the observed association of early high-dose rhGH treatment and early adrenarche? IGF-1 receptors have been shown to be expressed in the outer zone of the adrenal cortex during childhood (26) . In cultured human adrenocortical cells, IGF-1 exerted a direct positive effect on adrenocorticotropic hormone responsiveness and steroidogenesis, including DHEA production (27, 28) . In addition to the aforementioned-cited SGA studies, a clinical study in girls with Turner syndrome showed a significant rise of basal DHEAS and adrenocorticotropic hormone-stimulated DHEA in parallel to the IGF-1 increase after 6 months on rhGH treatment as compared with baseline and controls (29) . Therefore, a high serum IGF-1 concentration for years may be a relevant factor that positively stimulates the development and maturation of the zona reticularis in SRS. The second predictor of early adrenarche was low birthweight, but the correlation was moderate and was observed only in boys. In agreement with this finding, Dahlgren and colleagues (30) studied 53 children born SGA (41 boys; mean age, 8.8 years) and found a negative correlation between birthweight SDS and age-related serum DHEAS concentrations in the SGA group, with an age range of 4.7 to 9.2 years. This correlation disappeared in the older group (age range, 9.2 to 16 years), which was already postadrenarcheal or even pubertal. Studies on birthweight-discordant twins or triplets (31, 32) also suggest an effect of intrauterine growth on age at adrenarche. Francois and de Zegher (31) described 10 pairs of discordant siblings after twin or triplet pregnancy and found that at a median age of 8.2 years (range, 5.8 to 16 years), the SGA sibling had significantly higher serum DHEAS concentrations than the appropriate for gestational age sibling despite similar weight at the time of blood drawing (31). Schulte and colleagues (32) studied 16 twin pairs that were birthweight-discordant because of twin-to-twin transfusion syndrome and found significantly higher DHEAS serum concentrations at the age of 10 years in the twin with the lower birthweight.
Early gonadarche followed early adrenarche in boys, but not in girls. The ages at gonadarche observed in this study are in line with the recent report by Smeets et al. (11) , who studied a Dutch group of 62 SRS children with similar ages at gonadarche (11.4 and 10.2 years in boys and girls, respectively) and did not identify any case of precocious puberty. These very similar data suggest that, indeed, precocious puberty is less frequent in SRS than formerly thought. In our study, which included a substantial proportion of patients (37%) treated with GnRHa, age at gonadarche was only weakly or not at all correlated with residual growth after gonadarche. Girls treated with GnRHa for a mean duration of 2 years showed substantially more residual growth (~10 cm more) during puberty than girls who did not receive GnRHa treatment. This finding, which is based on 19 patients (11 treated), is consistent with the observation by Smeets et al. (11) add-on therapy with GnRHa has a beneficial effect on SRS, especially in girls.
Importantly, the effects of early adrenarche on final height were negligible. Possible explanations are the overall moderate acceleration of adrenarche, the only weak bone age acceleration during early adrenarche, and the relatively long time interval between adrenarche and pubarche as the first clinical sign of adrenarche, especially in boys. Interestingly, boys with early adrenarche were taller at gonadarche but ended up as short as the boys with normal adrenarche. This finding suggests that early adrenarche in boys with SRS is part of a tempo variant of growth that does not cause deterioration of adult height. This finding is in line with the findings of a previous longitudinal study in a mixed group of otherwise healthy girls with premature adrenarche who reached an adult height within their target (33) . Therefore, our data do not support a general therapeutic intervention in SRS aiming to enhance growth by suppressing adrenarche or inhibiting the aromatization of adrenal androgens. Exceptions to this recommendation may be the rare cases of very early adrenarche, when DHEAS rises shortly after minipuberty.
Our study has limitations that are inherent to the retrospective analysis of patient records on a very rare disorder covering a long time period. Lack of data and loss to follow-up limit the validity of the findings. Strengths of the study include the long duration of followup, the uniform documentation of patients' clinical and biochemical parameters in the records guided by experienced pediatric endocrinologists only, and the adherence to the same DHEAS assay over the whole time span.
In conclusion, early or premature adrenarche was more frequent in SRS than in the general population and was associated with early age at initiation of rhGH treatment. Response to rhGH treatment and adult height were not compromised by early adrenarche.
